Author

J. E. Axelrad

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:metagenomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

K. Cadwell· 2 shared A. Cassanovas-Massana· 1 shared A. I. Ko· 1 shared A. Iwasaki· 1 shared A. Korman· 1 shared A. M. Valero-Jimenez· 1 shared A. P. Sullivan· 1 shared A. Pironti· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

K. Cadwell

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tofacitinib uptake by patient-derived intestinal organoids predicts individual clinical responsiveness

K. K. Jang, D. Ercelen, J. Y. C. Cen Feng, S. Gurunathan, C. Zhou, A. Korman, L. Newell, D. Hudesman, D. R. Jones, P. Loke, J. E. Axelrad, K. Cadwell

This study uses patient-derived intestinal organoids to predict individual clinical responsiveness to tofacitinib in ulcerative colitis by assessing drug sensitivity and MATE1 expression.

bioRxiv · Mar 2, 2024Cell Biology

Gut microbiome dysbiosis during COVID-19 is associated with increased risk for bacteremia and microbial translocation.

M. Venzon, L. Bernard-Raichon, J. Klein, J. E. Axelrad, C. Zhang, G. A. Hussey, A. P. Sullivan, A. Cassanovas-Massana, M. G. Noval, A. M. Valero-Jimenez, J. Gago, G. Putzel, A. Pironti, E. Wilder, Yale IMPACT Research Team, , J. Schluter

The paper shows that gut microbiome dysbiosis in COVID-19 patients is linked to increased risk of bacteremia and microbial translocation.

bioRxiv · Jul 15, 2021 · PreprintMicrobiology